All In Biotech

Drug Trial Radar · NCT07708181

A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment

A Phase 2, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 2, 2026

Primary completion

Aug 11, 2027

Study completion Apr 19, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment

Conditions

  • Gout Arthritis

Interventions

  • SSGJ-613 100 mg Q12WDrug

    Participants will receive one s.c. injection of SSGJ-613 on Day 1、W12

  • SSGJ-613 200 mg Q12WDrug

    Participants will receive one s.c. injection of SSGJ-613 on Day 1、W12

  • SSGJ-613 100 mg Q4WDrug

    Participants will receive one s.c. injection of SSGJ-613 on Day 1、W4、W8、W12

  • Colchicine 0.5 mgDrug

    Participants will receive 0.5mg bid Colchicine for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers of acute gout flaresTime frame: 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.